Skip to main content
Equibles

Akos

Aktis Oncology, Inc. (AKTS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Aktis Oncology, Inc. publishes a filing, an earnings call transcript or a press release.

Get AKTS alerts

About Akos

Akos has spoken on 1 investor event across 1 company, most recently for Aktis Oncology, Inc. on May 27, 2026. Aktis Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aktis Oncology, Inc. includes Glenn Gormley (Board Member).

Akos on recent calls

“AKY2519 is our novel, potentially first-in-class miniprotein radioconjugate targeting B7H3-expressing Like other miniproteins from our proprietary radioconjugate platform, it combines high affinity with highly selective binding to its target, in this case B7H3, with pharmacological properties that allow for deep tumor…”
Other, AKTIS ONCOLOGY: AKY-2519 CLINICAL IMAGING AND DOSIMETRY DATA CONFERENCE CALL ·

Affiliation history

Company network

Leadership on record at Aktis Oncology, Inc.

Recent activity